WO2024254562A3 - Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite - Google Patents

Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite Download PDF

Info

Publication number
WO2024254562A3
WO2024254562A3 PCT/US2024/033155 US2024033155W WO2024254562A3 WO 2024254562 A3 WO2024254562 A3 WO 2024254562A3 US 2024033155 W US2024033155 W US 2024033155W WO 2024254562 A3 WO2024254562 A3 WO 2024254562A3
Authority
WO
WIPO (PCT)
Prior art keywords
variable heavy
immunoglobulin variable
reduced immunogenicity
modified immunoglobulin
heavy domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033155
Other languages
English (en)
Other versions
WO2024254562A2 (fr
Inventor
Patrick L. LUPARDUS
Deepti ROKKAM
Michael TOTAGRANDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthekine Inc
Original Assignee
Synthekine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc filed Critical Synthekine Inc
Priority to JP2025571136A priority Critical patent/JP2026521433A/ja
Priority to CN202480051018.6A priority patent/CN121941708A/zh
Priority to KR1020267000338A priority patent/KR20260021032A/ko
Priority to EP24820201.2A priority patent/EP4724499A2/fr
Priority to IL324785A priority patent/IL324785A/en
Priority to AU2024285577A priority patent/AU2024285577A1/en
Publication of WO2024254562A2 publication Critical patent/WO2024254562A2/fr
Publication of WO2024254562A3 publication Critical patent/WO2024254562A3/fr
Priority to MX2025014711A priority patent/MX2025014711A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne de manière générale des anticorps à domaine unique (sdAb), tels que des fragments polypeptidiques VH, VHH et scFv, comprenant des modifications C-terminales qui ont une liaison réduite ou éliminée à des anticorps préexistants endogènes, des polypeptides isolés comprenant de telles modifications, des nucléotides codant pour de tels polypeptides, et des procédés d'utilisation de tels polypeptides d'anticorps.
PCT/US2024/033155 2023-06-07 2024-06-07 Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite Ceased WO2024254562A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2025571136A JP2026521433A (ja) 2023-06-07 2024-06-07 低減した免疫原性を有する改変された免疫グロブリン可変重ドメイン
CN202480051018.6A CN121941708A (zh) 2023-06-07 2024-06-07 免疫原性降低的修饰免疫球蛋白可变重结构域
KR1020267000338A KR20260021032A (ko) 2023-06-07 2024-06-07 감소된 면역원성을 갖는 변형된 이뮤노글로불린 가변 중쇄 도메인
EP24820201.2A EP4724499A2 (fr) 2023-06-07 2024-06-07 Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite
IL324785A IL324785A (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity
AU2024285577A AU2024285577A1 (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity
MX2025014711A MX2025014711A (es) 2023-06-07 2025-12-05 Dominios pesados de variables de inmunoglobulina modificados que tienen inmunogenicidad reducida

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506797P 2023-06-07 2023-06-07
US63/506,797 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254562A2 WO2024254562A2 (fr) 2024-12-12
WO2024254562A3 true WO2024254562A3 (fr) 2025-03-20

Family

ID=93796476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033155 Ceased WO2024254562A2 (fr) 2023-06-07 2024-06-07 Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite

Country Status (8)

Country Link
EP (1) EP4724499A2 (fr)
JP (1) JP2026521433A (fr)
KR (1) KR20260021032A (fr)
CN (1) CN121941708A (fr)
AU (1) AU2024285577A1 (fr)
IL (1) IL324785A (fr)
MX (1) MX2025014711A (fr)
WO (1) WO2024254562A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172981A2 (fr) * 2016-03-29 2017-10-05 University Of Southern California Récepteurs antigéniques chimériques ciblant le cancer
WO2022040586A2 (fr) * 2020-08-21 2022-02-24 Novartis Ag Compositions et méthodes pour la génération in vivo de cellules exprimant car
WO2022061256A2 (fr) * 2020-09-21 2022-03-24 Systimmune, Inc. Complexe de liaison à l'egfr et son procédé de fabrication et d'utilisation
CN115703829A (zh) * 2021-08-16 2023-02-17 厦门大学 针对SARS-CoV-2的单域抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172981A2 (fr) * 2016-03-29 2017-10-05 University Of Southern California Récepteurs antigéniques chimériques ciblant le cancer
WO2022040586A2 (fr) * 2020-08-21 2022-02-24 Novartis Ag Compositions et méthodes pour la génération in vivo de cellules exprimant car
WO2022061256A2 (fr) * 2020-09-21 2022-03-24 Systimmune, Inc. Complexe de liaison à l'egfr et son procédé de fabrication et d'utilisation
CN115703829A (zh) * 2021-08-16 2023-02-17 厦门大学 针对SARS-CoV-2的单域抗体及其用途

Also Published As

Publication number Publication date
WO2024254562A2 (fr) 2024-12-12
IL324785A (en) 2026-01-01
JP2026521433A (ja) 2026-06-30
KR20260021032A (ko) 2026-02-12
CN121941708A (zh) 2026-04-28
MX2025014711A (es) 2026-06-01
AU2024285577A1 (en) 2025-12-04
EP4724499A2 (fr) 2026-04-15

Similar Documents

Publication Publication Date Title
IL305912A (en) Improved serum albumin binding agents
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
WO2018134235A8 (fr) Liants d'albumine sérique améliorés
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
WO2005056600B1 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
CA3242520A1 (fr) Anticorps tetraedriques
WO2023060137A3 (fr) Procédés et compositions comprenant des polypeptides de liaison b7-h3
ZA202404271B (en) Bispecific cd16a binders
MX2025013732A (es) Anticuerpos de dominio unico modificados
MX2022012021A (es) Peptidos de dominios knob autonomos.
CN111448214A (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
JP2021529524A5 (fr)
JP2024527020A5 (fr)
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
WO2023193732A1 (fr) Anticorps anti-ccr8 ou fragment de liaison à l'antigène de celui-ci
WO2024151737A3 (fr) Constructions d'anticorps spécifiques de cd19 et compositions associées
Li et al. Selection by phage display of nanobodies directed against hypoxia inducible factor‐1α (HIF‐1α)
WO2024102935A3 (fr) Domaines de liaison à l'antigène et leurs procédés d'utilisation
WO2024148232A3 (fr) Anticorps de protéine de liaison anti-il18 et leurs procédés d'utilisation
WO2024220498A3 (fr) Domaines de liaison à l'antigène et méthodes d'utilisation associées
MX2024006969A (es) Anticuerpos dlk1 y metodos de tratamiento del cancer.
JP2024532970A5 (fr)
MX2025013491A (es) Metodos y composiciones para reducir la viscosidad de los anticuerpos
WO2020168298A3 (fr) Compositions d'anticorps lym-1 et lym-2 et constructions car améliorées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820201

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024285577

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 202517120829

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024285577

Country of ref document: AU

Date of ref document: 20240607

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025571136

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014711

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1020267000338

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000338

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024820201

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 1020267000338

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2024820201

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: MX/A/2025/014711

Country of ref document: MX